Successful treatment of low‐risk myelodysplastic syndrome‐related anemia in patients with chronic kidney disease with daprodustat: A report of two cases
Hiroyoshi Kunimoto,
Takayuki Sakuma,
Takuma Ohashi,
Mayoko Shirafuta,
Hiroshi Teranaka,
Hideaki Nakajima
Affiliations
Hiroyoshi Kunimoto
Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan
Takayuki Sakuma
Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan
Takuma Ohashi
Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan
Mayoko Shirafuta
Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan
Hiroshi Teranaka
Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan
Hideaki Nakajima
Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan
Abstract Anemia is a major clinical manifestation seen in myelodysplastic syndromes (MDS). Treatment options for anemia in low‐risk MDS are limited. Especially, oral medication which is uniformly effective for anemia in low‐risk MDS is required. Hypoxia‐inducible factor (HIF) prolyl hydroxylase (HIF‐PH) inhibitors, such as daprodustat, are oral tablets effective for renal anemia. Pharmacological restoration of HIF activity by HIF‐PH inhibitors may be beneficial for MDS‐related anemia as well. Yet, their efficacy and safety against low‐risk MDS are unclear. Here, we report two cases of low‐risk MDS complicated with chronic kidney disease whose anemia responded to daprodustat treatment.
